TRANSLATE

Welcome to Our Parkinson's Place


I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please No advertisers, and No Information about Herbal treatments. This is a free site for all.
Thank you.


Wednesday, May 10, 2017

Parkinson’s gene mutation discovered in one third of cancers

May 10, 2017



A gene found in a hereditary form of Parkinson’s disease is mutated in a third of all human cancers – and helps regulate one of the disease’s most commonly activated cell signalling mechanisms, a new study reveals.
Scientists at The Institute of Cancer Research, London, analysed nearly 10,000 tumour samples from 28 different types of cancer, and found that the gene PARK2 was altered in over a third of tumours. 
Their study showed how loss of PARK2 can stimulate a crucial network of cancer-driving molecules in cells, called the PI3K/Akt pathway, through a well-researched tumour suppressor gene called PTEN.
The findings reveal a ‘missing link’ in one of the most commonly observed signalling pathways in cancer, showing how the PI3K/Akt pathway can be ramped up in the stressful, energy poor conditions often found inside tumours. 
The study, published in the journal Molecular Cell, was funded in the UK by the Medical Research Council and the ICR, and could help researchers understand how aggressive cancer cells can survive and proliferate in low energy conditions.
Loss of gene in tumours
Mutations in PARK2 have been found in a hereditary form of Parkinson’s disease, a degenerative condition which kills off cells in the brain. When the gene is depleted in cells, mitochondria – the energy factories of cells – become defective. But cancer cells have the ability to withstand the energy stress coming from defective mitochondria by ramping up PI3K/Akt signalling, through deactivating PTEN. 
Importantly, the researchers found that PARK2 was significantly under-expressed across many tumour types. Widespread loss or reduced PARK2 in tumours correlated with poorer survival chances for patients with diseases including brain, breast and lung cancer. 
The research indicates an intriguing link between mutations to PARK2 and the PTEN gene. In mice without working copies of PARK2, mutations to PTEN resulted in a much higher risk of developing tumours and poorer survival outcomes, compared with mice with functional PARK2
Study co-author Dr George Poulogiannis, leader of the Signalling and Cancer Metabolism team at the ICR, said: “Our study has highlighted that PARK2 loss is present in around a third of all cancers and has profound implications in understanding how cancer cells may support their proliferation and survival under conditions of nutrient deprivation. 
“In the future, tests that look for mutations to PARK2 may help to identify patients who have particularly aggressive forms of cancer that may respond to inhibitors of PI3K/Akt signalling”.
http://www.icr.ac.uk/news-archive/parkinson-s-gene-mutation-discovered-in-one-third-of-cancers

No comments:

Post a Comment